Leslie M. Shaw, PhD
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Clinical Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine
Contact InformationHospital of the University of Pennsylvania
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Email: Les.Shaw@uphs.upenn.edu; shawlmj@mail.med.upenn.edu
Specialty Division
Laboratory Medicine
Research Expertise
Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.
Clinical Expertise
Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.
Other Expertise
Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab.
Education
B.S. (Cum Laude, Chemistry), LeMoyne College, Syracuse, New York, 1962
Ph.D. (Biochemistry), S.U.N.Y. at Upstate Medical Center, 1968
Specialty Certification
American Board of Clinical Chemistry, 1973
American Board of Clinical Chemistry in Toxicological Chemistry, 1990
USC School of Medicine, Laboratory of Applied Pharmacokinetics, 1995
Postgraduate Training
NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970
Fellow, Neuroscience Research Program, 1969-1969
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972
Awards and Honors
Norman Kubasik Lectureship Award, Upstate New York AACC Meeting, 1992-1992
Outstanding Speaker Award, 1995, 1996, 1997, 2000, 2001, 2002, 2003, American Association for Clinical Chemistry, 1995-2003
Reinhold Award, Philadelphia Section, AACC, 1995-1995
The Peter C Nowell Teaching Award, University of Pennsylvania Medical Center, 1999-1999
IATDMCT Charles Pippenger Award for Outstanding Contributions in Therapeutic Drug Monitoring, 1999-1999
The Kevin Salhany, MD, Award for Excellence in Clinical Teaching; Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, 2005-2005
LeMoyne College - Distinguished Alumni Award, 2012-2012
AACC Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine., 2013
Memberships and Professional Organizations
American Chemical Society, 1962 - present
Alpha Sigma Nu, National Jesuit Honor Society, 1962 - 1964
American Association for Clinical Chemistry, 1972 - present
Philadelphia Section, American Association for Clinical Chemistry:, 1978 - Present
American Association for the Advancement of Science, 1978 - present
Philadelphia Section, American Association for Clinical Chemistry: 1996 (Program Chairman).
Philadelphia Section, American Association for Clinical Chemistry: 1978, 1978 - Present
International Federation of Clinical Chemistry, 1979 - present
AACC/NACB Task Force on Cyclosporine Monitoring, 1985 - 1987
National Academy of Clinical Biochemistry:, 1986 - present
International Association for Therapeutic Drug Monitoring and Clinical Toxicology, 1989 - present
Therapeutic Drug Monitoring and Clinical Toxicology Division of the AACC:, 1991 - Present
American Society for Mass Spectroscopy, 1991 - 1994
USP Council of Experts,, 2001 - 2002
Society of Toxicology, 2004 - 2007, 2004 - 2007
Alzheimers Association, 2005 - Present
Eli Lilly, 2011 - 2018
Alzheimers Association Global Biomarker Standardization Consortium., 2011 - Present
Roche (Member of Scientific Advisory Board), 2016 - Present
Cerebrospinal Fluid appropriate Use, Criteria Workgroup, Alzheimers Association., 2017 - 2018
FNIH Biomarker Consortium, plasma abeta project team, 2017 - ongoing
FNIH Biomarker Consortium Plasma Aβ Project Team., 2022 - Present
Selected Publications
Assessments of the utilities of CSF NPTX2 for disease progression in cognitively normal individuals who progress to clinical MCI and AD.
Shaw LM, Galasko D., Ann Neurol Invited Commentary In Press(): , 2023, In Press
Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape.
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Suzanne E. Schindler., Neuron. In Press(): , 2023 In Press
Plasma phosphorylated tau181 predicts cognitive and functional decline.
Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, Grossman M, Irwin DJ, Weintraub D, Lee EB, Wolk DA, Chen-Plotkin AS, Shaw LM; Alzheimer's Disease Neuroimaging Initiative., Ann Clin Transl Neurol. 10(1): 18-31, 2023, PMID:36518085
The performance of plasma amyloid beta measurement in predicting amyloid burden: a literature review.
Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, Lopez SC, Ovod V, Nakamura A, Shaw LM, Zetterberg H, Hansson O, Bateman RJ., Alzheimer's Res Ther. 14(1): 195, 2022, PMID:36575454
Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis.
Cousins KAQ, Shaw LM, Shellikeri S, Dratch L, Rosario L, Elman LB, Quinn C, Amado DA, Wolk DA, Tropea TF, Chen-Plotkin A, Irwin DJ, Grossman M, Lee EB, Trojanowski JQ, McMillan CT., Ann Neurol. 92(5): 807-818, 2022, PMID:35877814
Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.
Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS , Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, Fagan AM, Farlow M, Fox NC, Ghetti B, Goate AM, Gordon BA, Graff-Radford N, Day GS, Hassenstab J, Ikeuchi T, Jack CR Jr, Jagust WJ, Jucker M, Levin J, Massoumzadeh P, Masters CL, Martins R, McDade E, Mori H, Noble JM, Petersen RC, Ringman JM, Salloway S, Saykin AJ, Schofield PR, Shaw LM, Toga AW, Trojanowski JQ, Voglein J, Weninger S, Bateman RJ, Buckles VD, on behalf of the Dominantly Inherited Alzheimer Network (DIAN) and the Alzheimer's Disease Neuroimaging Initiative (ADNI)., Brain. 145(10): 3594-3607, 2022, PMID:35580594
Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Blennow K, Trojanowski JQ., Clin Chem. 68(10): 1336-37, 2022, PMID:36103266
Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders.
Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, Grossman M, Irwin DJ, Trojanowski JQ, Zetterberg H, Blennow K, Brinkmalm A., Alzheimers Dement., 2022, PMID:36239248
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ., Neurology. 98(7): , 2022, PMID:34906975
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity.
Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, et al., Alz Dementia, 2022
